Yuekang Pharmaceutical announced on August 5 that the company recently obtained the approval and issuance of the “Drug Clinical Trial Approval Notice” from the State Drug Administration to approve the use of YKYY017 nebulized inhalers to treat and prevent respiratory infections associated with the human coronavirus OC43.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.